Xeljanz Multidistrict Litigation Lawsuit – A Comprehensive Overview

The landscape of pharmaceutical litigation has seen a surge with the opening of multidistrict litigation (MDL) cases centered on the harm caused to patients by specific drugs. One such case which is currently receiving significant attention is the Xeljanz, Xeljanz XR, and Jakvinus multidistrict litigation lawsuit. This article will delve into the intricacies of this ongoing legal battle and its implications for both manufacturers and consumers alike.

What are Xeljanz, Xeljanz XR, and Jakvinus?

Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended release), and Jakvinus (tofacitinib’s version in Europe) are medications produced by Pfizer. Approved by the Food and Drug Administration (FDA), these drugs are primarily used to treat arthritis and other similar ailments. However, they have faced scrutiny due to the serious side effects they may potentially cause. [1]

The Cause for Legal Action:

The Xeljanz MDL arose after numerous patients alleged adverse side effects from taking the medication. These effects reportedly include blood clots, heart attacks, pulmonary embolism, deep vein thrombosis (DVT), and death, leading to the restructuring of the warning label by the FDA in 2019. [2]

The ongoing Xeljanz multidistrict litigation suit alleges that Pfizer failed in its duty to sufficiently warn consumers and medical professionals about the potential risks associated with using these products. The plaintiffs argue that had they known about these risks, they might have opted for different treatment options or monitored their health more scrupulously during treatment. [3]

Multidistrict Litigation (MDL):

In the American federal legal system, when large numbers of plaintiffs sue a defendant or defendants with related claims, these actions may be consolidated in one court for pretrial processes through an MDL. Centralization of these cases aims to prevent duplication of discovery, and inconsistent pretrial rulings, and conserve the resources of the parties, attorneys, and judiciary. [4]

Establishment of the Xeljanz MDL:

In December 2021, the United States Judicial Panel on Multidistrict Litigation (JPML) centralized litigation involving Xeljanz, Xeljanz XR, and Jakvinus. This centralization combines various federal lawsuits lodged against Pfizer into a single courtroom. The decision was mainly based on avoiding inconsistent rulings and conserving resources.

The Assignment:

The Xeljanz MDL was assigned to U.S. District Judge Paul G. Byron of the Middle District of Florida, known for his previous involvement in important drug and device injury MDLs. He will oversee the coordinated or consolidated pretrial proceedings. [5]

Future Implications:

While the establishment of the Xeljanz MDL is a significant milestone, it’s important to remember MDL is not a class action lawsuit. Each claimant maintains their lawsuit. Additionally, the creation of the MDL does not preclude new claims from being added. If you or a loved one suffered harm due to Xeljanz, Xeljanz XR, or Jakvinus, it may be in your best interest to consult a qualified attorney specializing in pharmaceutical litigation.

This Xeljanz MDL lawsuit highlights the accountability of pharmaceutical companies to ensure the safety of their products and provide accurate, comprehensive information on potential risks. This case will undoubtedly significantly impact future pharmaceutical litigation.

Please note, this blog article does not constitute legal advice. Always consult with a legal professional for personalized advice.

Disclaimer: The information contained in this article is for general informational purposes only and does not constitute legal advice. This article may not contain the most up-to-date legal standards and regulations. It is advised to seek professional legal counsel for personal advice.

If you or a loved one has been injured by Xeljanz, give us a call at the Michael Brady Lynch Firm at 888-585-5970.

Date: June 30, 2023

Author: Brandon Salter and Anoop Desai

Citations

[1] https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and

[2] https://www.fda.gov/drugs/drug-safety-and-availability/safety-trial-finds-risk-blood-clots-lungs-and-death-higher-dose-tofacitinib-xeljanz-xeljanz-xr

[3] https://www.drugwatch.com/xeljanz/lawsuits/

[4] https://www.jpml.uscourts.gov/sites/jpml/files/28_usc_1407.pdf

[5] https://www.flmd.uscourts.gov/judges/paul-byron

Oxbryta Recall Prompts Lawsuits: What You Need to Know

Oxbryta was marketed as a revolutionary drug to help people suffering from sickle cell disease manage their most painful symptoms. Oxbryta was manufactured by Global Blood Therapeutics (which was later bought by Pfizer) and approved by the FDA in 2019 for children and adults 12 years old and older. It was approved for children four years old and up in 2021. Alarming results from post-launch trials showed that Oxbryta may increase the symptoms of sickle cell disease instead of decreasing them.

Mass Tort Abuses in the Mormon Church: A Legal Perspective

In recent years, the Church of Jesus Christ of Latter-day Saints (LDS), commonly known as the Mormon Church, has faced increasing legal scrutiny due to allegations of widespread abuse and institutional cover-ups. have come forward with claims of sexual, emotional, and physical abuse, many of which involve church leaders or institutions. These lawsuits have begun to take the form of mass tort claims, as multiple plaintiffs allege a systemic pattern of negligence and concealment within the organization.

Understanding Copyright Law for OnlyFans Creators

OnlyFans has become a booming platform for influencers and content creators, allowing them to monetize their work directly through subscriptions. However, with the rise of digital content creation comes the inevitable challenge of copyright infringement. Many OnlyFans creators find their exclusive content stolen and redistributed on unaffiliated websites without their permission. If you’re an OnlyFans influencer facing this issue, you may have legal recourse to protect your rights.

Update on The New Maryland Child Sexual Abuse Law

Maryland recently made a landmark change to its legal landscape by eliminating the civil statute of limitations for child sexual abuse cases under the **Child Victims Act of 2023**. This law, upheld by the Maryland Supreme Court in February 2025, allows survivors to file lawsuits regardless of how much time has passed since the abuse occurred.

PIP Insurance Coverage Florida: How it Works

Florida is one of 12 “no-fault” insurance states, requiring drivers to carry Personal Injury Protection (PIP) insurance on vehicles operated in the state. PIP insurance allows injured drivers to receive compensation for damages and medical expenses by utilizing their insurance coverage.

An Update on PFAS Cases: New Contamination Sites in US

Per- and polyfluoroalkyl substances (PFAS), commonly known as “forever chemicals,” have been a growing concern due to their persistence in the environment and potential health risks. Recent developments have highlighted new contamination sites and legal actions aimed at addressing these issues across the United States.

Suboxone Film: Design Defects, Warning Claims, and Health Risks

Suboxone, a medication that combines buprenorphine and naloxone, has been instrumental in helping individuals recover from opioid addiction. However, recent concerns over its film formulation have highlighted serious health risks, particularly regarding dental decay and tooth loss.

Mounjaro Lawsuits: Popular Drug Used for Weight Loss Causes Stomach Paralysis

Mounjaro is an injectable drug approved by the FDA to treat type 2 diabetes. Although approved for managing diabetes, studies indicate that Mounjaro’s active ingredient, tirzepatide, may be more effective than Wegovy or Ozempic for weight loss. This has led to a rise in patients using Mounjaro off-label for weight management.

Nursing Home Abuse: An Overview

Nursing home abuse involves the mistreatment, neglect, or exploitation of residents in long-term care facilities. This includes skilled nursing homes, assisted living facilities, and other institutions responsible for the care of elderly or vulnerable adults. Under both federal and state laws, these facilities are required to provide residents with a safe, digniﬁed, and compassionate environment.

Oxbryta Recall: What You Need to Know

Oxbryta is a prescription medication developed to help people with sickle cell disease (SCD). It works by improving the oxygen-carrying ability of red blood cells and reducing the complications that come with SCD, like pain crises and organ damage. While it’s been seen as a breakthrough for managing this condition, a recent recall has raised serious concerns about its safety.

Xeljanz Multidistrict Litigation Lawsuit – A Comprehensive Overview

What Our Clients Are Saying